Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
Key facts
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 11 people enrolled
- Started
- 1 Jun 2021
- Ended
- 30 Apr 2025
- Type of study
- Interventional
- Treatments tested
- Nintedanib 150 milligrams [Ofev]
- Record updated
- 2 September 2025
- Why it stopped
- Slow recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 1. 18 years and older 2. Diagnosis of autoimmune myopathy (dermatomyositis, polymyositis, overlap myositis or anti-synthetase syndrome) as diagnosed by a rheumatologist; Interstitial lung disease confirmed by high resolution CT scan (Extent of disease 10% or more on CT done within 12 months of enrolment) with evidence of fibrosis, defined as reticular abnormality with traction bronchiectasis with or without honeycombing; Evidence of progressive disease within 24 months of screening visit:; Clinically significant decline in Forced Vital Capacity (FVC) % pred based on a relative decline of >=10%; Marginal decline in FVC % pred based on a relative decline of .>=5-<10% combined with worsening of respiratory symptoms; Marginal decline in FVC % pred based on a relative decline of >=5-<10% combined with increasing extent of fibrotic changes on chest imaging; Worsening of respiratory symptoms such as cough or shortness of breath as well as increasing extent of fibrotic changes on chest imaging as per radiologist or pulmonologist who read the scan 5. Current and ongoing treatment with immunosuppressive medications, on a stable medication regimen and dosage for at least 6 weeks (considered standard of care medical therapy) Concomitant medications allowed are:; <!-- -->; mycophenolate,; azathioprine,; tacrolimus,; cyclosporine,; rituximab (injection within the last year),; prednisone low dose =<20 mg daily,; Intravenous immunoglobulins
Who cannot take part
- Contraindication to treatment with nintedanib (based on Canadian labeling)
- Hypersensitivity to nintedanib, peanut or soy
- Patient with risks factors of aneurysm or artery dissection, such as known history of aneurysm or uncontrolled hypertension
- Creatinine clearance <30 mL/min
- The female patient is pregnant, plans to become pregnant during the course of the study, or is breastfeeding
- The male patient plans to father a child during the course of the study
- Elevated liver enzymes greater than 1.5 times the upper limit of normal
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
There is likely a role for using anti-fibrotic medications in patients with myositis-associated interstitial lung disease (MA-ILD) to slow down disease progression, especially in patients who have fibrotic and progressive disease. These patients however are currently being excluded from clinical trials of anti-fibrotic agents in progressive ILD because of the concomitant use of immunosuppression. The benefit of anti-fibrotic agents is being assessed in other rheumatic diseases and should be assessed in MA-ILD as well. They are a unique group of patients with a heterogeneous disease, and are much more frequently on concomitant immune-modulating therapy. As such, they should be studied on their own in separate clinical trials, and the use of nintedanib should be studied as an addition to standard of care immunosuppression.
Read full original descriptionShow less
The objective of this study is to assess safety and tolerability of nintedanib in patients with MA-ILD.
The group in the trial
- Nintedanib treatmentTreatment being tested
Single arm treatment with nintedanib
Treatment: Nintedanib 150 milligrams [Ofev]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 2 September 2025